drugset / Trial / NCT00403962

A Combination Therapy In Patients With Social Anxiety Disorder

NCT00403962

Phase 2 Completed 204 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)

Timeline

Start
2004-11
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule
Subject Vestipitant Small molecule

Indications